Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

A legfontosabb adatok

Ki végzi
ModernaTX, Inc.
Hol
Decatur, Hialeah, Hollywood, Houston, Lenexa, Marlton, Miami, Philadelphia, River Forest, San Antonio, Sugar Land és Tomball (Egyesült Államok)Mind a 12 helyszín megnézéseMég 1 másik országban, 4 helyszínen
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
931 fő vett részt
Kezdés
2024. júl. 15.
Befejezés
2025. szept. 25.
A vizsgálat típusa
Beavatkozással járó, 6 csoport
A vizsgált kezelések
  • mRNA-1083
A regiszteradat frissítve
2026. október 8.

Ki vehet részt

Életkor
50 év – 64 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Investigator assessment that the participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures
  • Participants of nonchildbearing potential may be enrolled in the study
  • Participants who could become pregnant: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
  • Have received an influenza vaccine in the previous season (since September 2023 for Part 1, since Sep 2024 for Part 2)

Ki nem vehet részt

  • Received corticosteroids at ≥10 milligrams (mg)/day of prednisone or equivalent for >14 days in total within 90 days prior to Day 1 or is anticipating the need for corticosteroids at any time during the study
  • Received systemic immunosuppressive treatment, including long-acting biological therapies that affect immune responses (e.g., infliximab), within 180 days prior to Day 1 or plans to do so during the study
  • Received or plans to receive any vaccine authorized or approved by a local health agency within 28 days prior to Day 1 or plans to do so within 28 days post study injection
  • Received a licensed seasonal influenza vaccine within 150 days prior to Day 1
  • Received a licensed/authorized SARS-CoV-2 vaccine within 90 days prior to Day 1
  • Received any investigational influenza vaccine, investigational coronavirus disease 2019 (COVID-19) vaccine, or investigational combination vaccine for influenza and COVID-19 within 12 months prior to Day 1. Participants from mRNA-1083-P201 Part 1 will also be excluded from Part 2; Other protocol-defined inclusion/exclusion criteria may apply
  • Reported diagnosis or condition that is associated with increased risk of severe influenza disease or complications, including individuals with chronic medical conditions
  • Reported history of congenital or acquired immunodeficiency, immunosuppressive condition, asplenia, or recurrent severe infections
  • History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any of the following: mRNA vaccine or therapeutic; components of an mRNA vaccine or therapeutic; influenza vaccine; or components of an influenza vaccine, including egg protein

Helyszínek itt: Egyesült Államok

Még 1 másik országban, 4 helyszínen

  • Cenexel IRADecatur, Egyesült Államok
  • Indago Research & Health Center, IncHialeah, Egyesült Államok
  • CenExel RCAHollywood, Egyesült Államok
  • DM Clinical Research - Cyfair Clinical Research Center - PPDSHouston, Egyesült Államok
  • JCCTLenexa, Egyesült Államok
  • Hassman Research Institute - Berlin - CenExel - PPDSMarlton, Egyesült Államok
  • Suncoast Research Group, LLC dba Flourish ResearchMiami, Egyesült Államok
  • DM Clinical Research - PhiladelphiaPhiladelphia, Egyesült Államok
  • DM Clinical Research - River ForestRiver Forest, Egyesült Államok
  • Clinical Trials of Texas, LLC., dba Flourish ResearchSan Antonio, Egyesült Államok
  • DM Clinical Research - SugarlandSugar Land, Egyesült Államok
  • DM Clinical Research - Tomball MDCTomball, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to <65 years of age.

A vizsgálat 6 csoportja

  • Part 1 Group 1 - mRNA-1083 Lot AA vizsgált kezelés

    Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 1.

    Kezelés: mRNA-1083

  • Part 1 Group 2 - mRNA-1083 Lot BA vizsgált kezelés

    Participants will receive mRNA-1083 Lot B as a single injection on Day 1 in Part 1.

    Kezelés: mRNA-1083

  • Part 1 Group 3 - mRNA-1083 Lot CA vizsgált kezelés

    Participants will receive mRNA-1083 Lot C as a single injection on Day 1 in Part 1.

    Kezelés: mRNA-1083

  • Part 1 Group 4 - mRNA-1083 Lot DA vizsgált kezelés

    Participants will receive mRNA-1083 Lot D as a single injection on Day 1 in Part 1.

    Kezelés: mRNA-1083

  • Part 2 Group 5 - mRNA-1083 Lot AA vizsgált kezelés

    Participants will receive mRNA-1083 Lot A as a single injection on Day 1 in Part 2.

    Kezelés: mRNA-1083

  • Part 2 Group 6 - mRNA-1083 Lot EA vizsgált kezelés

    Participants will receive mRNA-1083 Lot E as a single injection on Day 1 in Part 2.

    Kezelés: mRNA-1083

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity in Relation to the Product Attributes of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Adults ≥50 to <65 Years of Age
A regiszteradat frissítve
2026. október 8.